Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 28;14(23):5853.
doi: 10.3390/cancers14235853.

Locoregional Approaches in Cholangiocarcinoma Treatment

Affiliations
Review

Locoregional Approaches in Cholangiocarcinoma Treatment

Alexander E Hare et al. Cancers (Basel). .

Abstract

Cholangiocarcinoma (CCA) is a rare hepatic malignant tumor with poor prognosis due to late detection and anatomic factors limiting the applicability of surgical resection. Without surgical resection, palliation is the most common approach. In non-surgical cases contained within the liver, locoregional therapies provide the best chance for increased survival and disease control. The most common methods, transarterial chemoembolization and transarterial radioembolization, target tumors by embolizing their blood supply and limiting the tumor's ability to metabolize. Other treatments induce direct damage via thermal ablation to tumor tissue to mediate their anti-tumor efficacy. Recent studies have begun to explore roles for these therapies outside their previous role of palliation. This review will outline the mechanisms of each of these treatments, along with their effects on overall survival, while comparing these to non-locoregional therapies.

Keywords: ablation; cholangiocarcinoma; transarterial chemoembolization; transarterial embolization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Saha S.K., Zhu A.X., Fuchs C.S., Brooks G.A. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21:594–599. doi: 10.1634/theoncologist.2015-0446. - DOI - PMC - PubMed
    1. Sripa B., Pairojkul C. Cholangiocarcinoma: Lessons from Thailand. Curr. Opin. Gastroenterol. 2008;24:349–356. doi: 10.1097/MOG.0b013e3282fbf9b3. - DOI - PMC - PubMed
    1. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed
    1. Khan A.S., Dageforde L.A. Cholangiocarcinoma. Surg. Clin. N. Am. 2019;99:315–335. doi: 10.1016/j.suc.2018.12.004. - DOI - PubMed
    1. Blechacz B., Komuta M., Roskams T., Gores G.J. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011;8:512–522. doi: 10.1038/nrgastro.2011.131. - DOI - PMC - PubMed

LinkOut - more resources